Genetics of Alzheimer's disease: New evidences for an old hypothesis?

Current Opinion in Genetics and Development

Volumn 21, Issue 3, 2011, Pages 295-301

  Lambert, Jean Charles ^a,b,c   Amouyel, Philippe ^a,b,c  

^a INSERM   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

^c UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR;

ALZHEIMER DISEASE; AMYLOID PLAQUE; APOLIPOPROTEIN E GENE; ATTRIBUTABLE RISK; BLOOD BRAIN BARRIER; BRIDGING INTEGRATOR 1 GENE; CLUSTERIN GENE; COMPLEMENT COMPONENT RECEPTOR 1 GENE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MISSENSE MUTATION; MONOGENIC DISORDER; OLIGOMERIZATION; PATHOPHYSIOLOGY; PHOSPHATIDYLINOSITOL BINDING CLATHRIN ASSEMBLY PROTEIN GENE; PRIORITY JOURNAL; REVIEW; SORCS1 GENE; SORL1 GENE; VASCULAR AMYLOIDOSIS;

EID: 79957604912     PISSN: 0959437X     EISSN: 18790380     Source Type: Journal    
DOI: 10.1016/j.gde.2011.02.002     Document Type: Review

References (57)

1. Hardy J., Selkoe D. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
2. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997, 20:154-159.
3. Small S.A., Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008, 60:534-542.
4. Gatz M., Reynolds C.A., Fratiglioni L., Johansson B., Mortimer J.A., Berg S., Fiske A., Pedersen N.L. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 2006, 63:168-174.
5. Sullivan P.F., Kendler K.S., Neale M.C. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003, 60:1187-1192.
6. Elbein S.C. The genetics of human noninsulin-dependent (type 2) diabetes mellitus. J Nutr 1997, 127:1891S-1896S.
7. Warner T.T., Schapira A.H. Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol 2003, 53:S16-S23.
8. Lambert J.C., Amouyel P. Genetic heterogeneity of Alzheimer's disease: complexity and advances. Psychoneuroendocrinology 2007, 32:S62-S70.
9. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., Risch N., van Duijn C.M. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997, 278:1349-1356.
10. Bertram L., McQueen M.B., Mullin K., Blacker D., Tanzi R.E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007, 39:17-23.
11. Li H., Wetten S., Li L., St Jean P.L., Upmanyu R., Surh L., Hosford D., Barnes M.R., Briley J.D., Borrie M., et al. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol 2008, 65:45-53.
12. Reiman E.M., Webster J.A., Myers A.J., Hardy J., Dunckley T., Zismann V.L., Joshipura K.D., Pearson J.V., Hu-Lince D., Huentelman M.J., et al. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron 2007, 54:713-720.
13. Abraham R., Moskvina V., Sims R., Hollingworth P., Morgan A., Georgieva L., Dowzell K., Cichon S., Hillmer A.M., O'Donovan M.C., et al. A genome-wide association study for late-onset Alzheimer's disease using DNA pooling. BMC Med Genomics 2008, 1:44.
14. Bertram L., Lange C., Mullin K., Parkinson M., Hsiao M., Hogan M.F., Schjeide B.M., Hooli B., Divito J., Ionita I., et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet 2008, 83:623-632.
15. Carrasquillo M.M., Zou F., Pankratz V.S., Wilcox S.L., Ma L., Walker L.P., Younkin S.G., Younkin C.S., Younkin L.H., Bisceglio G.D., et al. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet 2009, 41:192-198.
16. Beecham G.W., Martin E.R., Li Y.J., Slifer M.A., Gilbert J.R., Haines J.L., Pericak-Vance M.A. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet 2009, 84:35-43.
17. Lambert J.C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M.J., Tavernier B., et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009, 41:1094-1099.
18. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Williams A., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009, 41:1088-1093.
19. Seshadri S., Fitzpatrick A.L., Ikram M.A., DeStefano A.L., Gudnason V., Boada M., Bis J.C., Smith A.V., Carassquillo M.M., Lambert J.C., et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010, 303:1832-1840.
20. Corneveaux J.J., Myers A.J., Allen A.N., Pruzin J.J., Ramirez M., Engel A., Nalls M.A., Chen K., Lee W., Chewning K., et al. Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet 2010, 19:3295-3301.
21. Carrasquillo M.M., Belbin O., Hunter T.A., Ma L., Bisceglio G.D., Zou F., Crook J.E., Pankratz V.S., Dickson D.W., Graff-Radford N.R., et al. Replication of CLU, CR1, and PICALM associations with Alzheimer disease. Arch Neurol 2010, 67:961-964.
22. Jun G., Naj A.C., Beecham G.W., Wang L.S., Buros J., Gallins P.J., Buxbaum J.D., Ertekin-Taner N., Fallin M.D., Friedland R., et al. Meta-analysis Confirms CR1. CLU, and PICALM as Alzheimer Disease Risk Loci and Reveals Interactions With APOE Genotypes. Arch Neurol 2010, 67:1473-1484.
23. Schjeide B.M., Schnack C., Lambert J.-C., Lill C.M., Kirchheiner J., Tumani H., Otto M., Tanzi R.E., Lehrach H., Amouyel P., et al. The role of CLU. CR1, and PICALM on Alzheimer's disease risk and CSF biomarker levels. Arch Gen Psychiatry 2011, 68:207-213.
24. Yu J.T., Li L., Zhu Q.X., Zhang Q., Zhang W., Wu Z.C., Guan J., Tan L. Implication of CLU gene polymorphisms in Chinese patients with Alzheimer's disease. Clin Chim Acta 2010, 411:1516-1519.
25. Zhang Q., Yu J.T., Zhu Q.X., Zhang W., Wu Z.C., Miao D., Tan L. Complement receptor 1 polymorphisms and risk of late-onset Alzheimer's disease. Brain Res 2010, 1348:216-221.
26. Feulner T.M., Laws S.M., Friedrich P., Wagenpfeil S., Wurst S.H., Riehle C., Kuhn K.A., Krawczak M., Schreiber S., Nikolaus S., et al. Examination of the current top candidate genes for AD in a genome-wide association study. Mol Psychiatry 2010, 15:756-766.
27. Laumet G., Chouraki V., Grenier-Boley B., Legry V., Heath S., Zelenika D., Fievet N., Hannequin D., Delepine M., Pasquier F., et al. Systematic analysis of candidate genes for Alzheimer's disease in a French, genome-wide association study. J Alzheimers Dis 2010, 20:1181-1188.
28. Rogaeva E., Meng Y., Lee J.H., Gu Y., Kawarai T., Zou F., Katayama T., Baldwin C.T., Cheng R., Hasegawa H., et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 2007, 39:168-177.
29. Grupe A., Li Y., Rowland C., Nowotny P., Hinrichs A.L., Smemo S., Kauwe J.S., Maxwell T.J., Cherny S., Doil L., et al. A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease. Am J Hum Genet 2006, 78:78-88.
30. Kim J., Basak J.M., Holtzman D.M. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009, 63:287-303.
31. Deane R., Sagare A., Hamm K., Parisi M., Lane S., Finn M.B., Holtzman D.M., Zlokovic B.V. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 2008, 118:4002-4013.
32. Kim J., Castellano J.M., Jiang H., Basak J.M., Parsadanian M., Pham V., Mason S.M., Paul S.M., Holtzman D.M. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron 2009, 64:632-644.
33. Lambert J.C., Mann D., Richard F., Tian J., Shi J., Thaker U., Merrot S., Harris J., Frigard B., Iwatsubo T., et al. Is there a relation between APOE expression and brain amyloid load in Alzheimer's disease?. J Neurol Neurosurg Psychiatry 2005, 76:928-933.
34. Artiga M.J., Bullido M.J., Sastre I., Recuero M., García M.A., Aldudo J., Vázquez J., Valdivieso F. Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene. FEBS Lett 1998, 421:105-108.
35. Lambert J.C., Coyle N., Lendon C. The allelic modulation of apolipoprotein E expression by oestrogen: potential relevance for Alzheimer's disease. J Med Genet 2004, 41:104-112.
36. Lambert J.C., Mann D., Goumidi L., Harris J., Amouyel P., Iwatsubo T., Lendon C., Chartier-Harlin M.C. Effect of the APOE promoter polymorphisms on cerebral amyloid peptide deposition in Alzheimer's disease. Lancet 2001, 357:608-609.
37. Lambert J.C., Araria-Goumidi L., Myllykangas L., Ellis C., Wang J.C., Bullido M.J., Harris J.M., Artiga M.J., Hernandez D., Kwon J.M., et al. Contribution of APOE promoter polymorphisms to Alzheimer's disease risk. Neurology 2002, 59:59-66.
38. Roheim P.S., Carey M., Forte T., Vega G.L. Apolipoproteins in human cerebrospinal fluid. Proc Natl Acad Sci USA 1979, 76:4646-4649.
39. May P.C., Finch C.E. Sulfated glycoprotein 2: new relationships of this multifunctional protein to neurodegeneration. Trends Neurosci 1992, 15:391-396.
40. DeMattos R.B., Cirrito J.R., Parsadanian M., May P.C., O'Dell M.A., Taylor J.W., Harmony J.A., Aronow B.J., Bales K.R., Paul S.M., et al. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 2004, 41:193-202.
41. Wyss-Coray T., Yan F., Lin A.H., Lambris J.D., Alexander J.J., Quigg R.J., Masliah E. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci USA 2002, 99:10837-10842.
42. Singhrao S.K., Neal J.W., Rushmere N.K., Morgan B.P., Gasque P. Differential expression of individual complement regulators in the brain and choroid plexus. Lab Invest 1999, 79:1247-1259.
43. Rogers J., Li R., Mastroeni D., Grover A., Leonard B., Ahern G., Cao P., Kolody H., Vedders L., Kolb W.P., Sabbagh M. Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes. Neurobiol Aging 2006, 27:1733-1739.
44. Emerich D.F., Skinner S.J., Borlongan C.V., Vasconcellos A.V., Thanos C.G. The choroid plexus in the rise, fall and repair of the brain. Bioessays 2005, 27:262-274.
45. Vercellino M., Votta B., Condello C., Piacentino C., Romagnolo A., Merola A., Capello E., Mancardi G.L., Mutani R., Giordana M.T., et al. Involvement of the choroid plexus in multiple sclerosis autoimmune inflammation: a neuropathological study. J Neuroimmunol 2008, 199:133-141.
46. Lambert J.C., Grenier-Boley B., Chouraki V., Heath S., Zelenika D., Fievet N., Hannequin D., Pasquier F., Hanon O., Brice A., et al. Implication of the immune system in Alzheimer's disease: evidence from genome-wide pathway analysis. J Alzheimers Dis 2010, 20:1107-1118.
47. Geylis V., Kourilov V., Meiner Z., Nennesmo I., Bogdanovic N., Steinitz M. Human monoclonal antibodies against amyloid-beta from healthy adults. Neurobiol Aging 2005, 26:597-606.
48. Kellner A., Matschke J., Bernreuther C., Moch H., Ferrer I., Glatzel M. Autoantibodies against beta-amyloid are common in Alzheimer's disease and help control plaque burden. Ann Neurol 2005, 65:24-31.
49. Tebar F., Bohlander S.K., Sorkin A. Clathrin assembly lymphoid myeloid leukemia (CALM) protein: localization in endocytic-coated pits, interactions with clathrin, and the impact of overexpression on clathrin-mediated traffic. Mol Biol Cell 1999, 10:2687-2702.
50. Leprince C., Romero F., Cussac D., Vayssiere B., Berger R., Tavitian A., Camonis J.H. A new member of the amphiphysin family connecting endocytosis and signal transduction pathways. J Biol Chem 1997, 272:15101-15105.
51. Baig S., Joseph S.A., Tayler H., Abraham R., Owen M.J., Williams J., Kehoe P.G., Love S. Distribution and expression of picalm in Alzheimer disease. J Neuropathol Exp Neurol 2010, 69:1071-1077.
52. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003, 9:448-452.
53. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., DeLong C.A., Wu S., Wu X., Holtzman D.M., Paul S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002, 5:452-457.
54. Schneider J.A., Bennett D.A. Where vascular meets neurodegenerative disease. Stroke 2010, 41:S144-S146.
55. Bensemain F., Hot D., Ferreira S., Dumont J., Bombois S., Maurage C.A., Huot L., Hermant X., Levillain E., Hubans C., et al. Evidence for induction of the ornithine transcarbamylase expression in Alzheimer's disease. Mol Psychiatry 2009, 14:106-116.
56. Chapuis J., Hot D., Hansmannel F., Kerdraon O., Ferreira S., Hubans C., Maurage C.A., Huot L., Bensemain F., Laumet G., et al. Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. Mol Psychiatry 2009, 14:1004-1016.
57. Mawuenyega K.G., Sigurdson W., Ovod V., Munsell L., Kasten T., Morris J.C., Yarasheski K.E., Bateman R.J. Decreased clearance of CNS {beta}-amyloid in Alzheimer's disease. Science 2010, 330:1774.